Background: Sporadic Creutzfeldt-Jakob disease is classified according to the genotype at polymorphic codon 129 (M or V) of the prion protein (PrP) gene and the type (1 or 2) of abnormal isoform of PrP (PrP
Background
Creutzfeldt-Jakob disease (CJD) is a lethal transmissible neurodegenerative disease caused by an abnormal isoform of prion protein (PrP Sc ), which is converted from the normal cellular isoform (PrP C ) [1] . There is a polymorphism (methionine, M; or valine, V) at codon 129 of the prion protein (PrP) gene. Parchi and colleagues reported that the codon 129 genotype (M/M, M/V, or V/V) and the type (type 1 or type 2) of PrP Sc in the brain are major determinants of the clinicopathological phenotypes of sporadic CJD (sCJD) [2] [3] [4] [5] . Type 1 and type 2 PrP Sc are distinguishable according to the size of the proteinase K (PK)-resistant core of PrP Sc (21 and 19 kDa, respectively), reflecting differences in the PK-cleavage site (at residues 82 and 97, respectively) [6] . According to this molecular typing system, sCJD is classified into six subgroups (MM1, MM2, MV1, MV2, VV1, or VV2). In addition, MM2 can be divided into two subgroups based on histopathological criteria (MM2C, cortical form showing a predominant cortical pathology; or MM2T, thalamic form showing characteristic atrophy of thalamic and inferior olivary nuclei) [4] . This Parchi's classification based on genotyping, PrP Sc typing, and histotyping, has been widely used compared with an alternative classification system proposed by others [7, 8] .
Among the seven sCJD subgroups, the most complicated entity is MV2, which accounts for 11% of total sCJD [5] . Since MV2 shows wide phenotypic variations, Parchi and colleagues have proposed dividing this heterogeneous entity based on histopathological criteria (MV2C showing a predominant cortical pathology or MV2K showing kuru type PrP amyloid plaques) [9] . Moreover, the co-occurrence of these histotypes in the same brain (denoted as MV2K + C) has also been reported [9] . MV2K is the most common subgroup in MV2 (8% of total sCJD cases), whereas MV2C is very rare (< 0.5%) [5, 9] . MV2K + C is relatively common but sometimes misdiagnosed as MV2K even by experts of CJD surveillance centers [10] . Besides these complicated histotypes, type 2 PrP Sc in certain MV2 cases shows atypical features, i.e., wide, heterogeneous fragments that migrate at approximately 20 to 19 kDa and are sometimes visible as doublets [4, 11, 12] . The atypical type 2 PrP Sc has been reported in MV2K and MV2K + C but not in MV2C. The molecular mechanisms of the atypical type 2 PrP Sc formation remain elusive. In addition, the atypical type 2 PrP Sc has not been recapitulated in an experimental transmission of MV2K to PrP-humanized mice carrying the 129M/V genotype [13] .
To characterize the MV2 subgroups in detail and to resolve their complicated pathogenesis, we performed a comprehensive analysis of the MV2 subgroups based on histopathological, molecular and transmission properties.
Methods

Patients
CJD cases included in this study were patients with clinically, genetically and histopathologically proven sCJD. Brain tissues were obtained at autopsy from CJD patients after receiving informed consent for research use. The diagnosis of sCJD, histotype, and PrP Sc type were confirmed by PrP immunohistochemistry and western blot analysis [14, 15] . The genotype and the absence of mutations in the open reading frame of the PrP gene were determined by sequence analysis as described [16] . According to Parchi's classification [4, 5] , these sCJD cases were classified as follows: MM1, 1 case; MM2C, 1 case; VV2, 1 case; MV2C, 1 case; MV2K, 1 case; and MV2K + C, 1 case. These patients showed the typical phenotypes of each sCJD subgroup in the clinicopathological and biochemical examinations. Ethical approval for these studies was obtained from the Ethical Committee of Tohoku University Graduate School of Medicine. All experiments carried out on humans were in compliance with the Helsinki Declaration.
Transmission experiments
Brain homogenates (10%) were prepared as described [17] . Intracerebral transmission to PrP-humanized mice was performed using 20 μl of the homogenates [15] . The production of the knock-in mice expressing human PrP with the 129M/M genotype (Ki-Hu129M/M), Ki-Hu129M/V, and Ki-Hu129V/V has been reported [17, 18] . The expression levels of human PrP in the brains of these knock-in mice were identical to the level observed in wild-type mouse. The inoculated mice were sacrificed after the onset of disease or at death. One hemisphere of the brain was fixed in 10% buffered formalin for immunohistochemistry, and the other hemisphere was immediately frozen for western blotting. Ethical approval for these experiments using mice was obtained from Animal Care and Use Committee of Tohoku University Graduate School of Medicine.
Immunohistochemistry
Formalin-fixed brain tissues were treated with formic acid (99% for human tissues or 60% for mouse tissues) for 1 hour to inactivate the infectivity, and embedded in paraffin. Tissue sections were pretreated by hydrolytic autoclaving before PrP immunohistochemistry [14] . The anti-PrP monoclonal antibodies 3F4 [19] and #71 [20, 21] were used as the primary antibodies for human sections, and anti-PrP antiserum PrP-N [22] was used as the primary antibody for mouse sections. Goat-anti-mouse immunoglobulin polyclonal antibody labelled with the peroxidase-conjugated dextran polymer, EnVision + (Dako) and anti-rabbit EnVision + were used as the secondary antibodies. For the quantification of PrP plaques in the patient brains, at least six representative digital microscopy images were taken at 10× magnification from each brain region and analyzed using ImageJ software (rsb.info.nih. gov/ij). The number of PrP plaques was manually counted, and the mean plaque density in each brain region was calculated.
Western blotting
PrP
Sc was extracted from human or mouse brains with collagenase treatment as described [23] . For deglycosylation of PrP Sc , samples were digested with PNGaseF (New England Biolabs) as reported [24] . Protein samples were subjected to SDS-PAGE using 15% Tris-glycine long gels of 15 cm length and western blotting [18] . Type 1 PrP Sc -and type 2 PrP Sc -specific polyclonal antibodies (designated as Tohoku 1 (T1) and Tohoku 2 (T2), respectively [25] ) and the 3F4 antibody were used as the primary antibodies. Anti-rabbit EnVision + and anti-mouse EnVision + were used as the secondary antibodies. The signal intensities of the western blots were quantified with Quantity One software using an imaging device VersaDoc 5000 (Bio-Rad Laboratories).
Statistical analysis
Incubation times and the signal intensities of PrP Sc bands are expressed as mean ± SEM.
Results
Histotyping and molecular typing of MV2.
At first, we performed histopathological analysis of the three subgroups of MV2 (MV2K, MV2K + C, and MV2C; Parchi's classification [4, 5] is used in this paper). MV2K showed unicentric PrP amyloid plaques, kuru plaques, throughout the cerebral grey matter and the cerebellum as reported previously (Figure 1a , Additional file 1: Figure S1a , e) [4] . These plaques were prominent especially in the granular cell layer of the cerebellum. Figure S1c , d, g, h) [4, 9] . The cerebellum of MV2K + C contained numerous PrP plaques in the granular cell layer. Thus, MV2K + C showed mixed histotypes, i.e., a mixture of the MV2C/MM2C phenotype and MV2K phenotype. PrP plaques were absent in the brain of MV2C even in the granular cell layer of the cerebellum. Instead, MV2C and MM2C showed focal amorphous patchy PrP deposition in the molecular layer of the cerebellum as reported [5] . Thus, the three MV2 subgroups exhibited clearly different histotypes.
Next we performed western blot analysis of PrP Sc in the brains of three MV2 subgroups using PrP Sc typespecific antibodies and a conventional anti-PrP antibody 3F4 that detects all PrP Sc types. , which is observed in a part of dura mater-graft associated CJD [25] . Type 2 PrP Sc -specific antibody Tohoku 2 (T2) specifically detects the N-terminal PK-cleavage site of type 2 PrP Sc (at residue 97) [25] . In the conventional western blot analysis using the anti-PrP antibody 3F4, MV2K and MV2K + C had heterogeneous unglycosylated bands located at 20 kDa to 19 kDa as reported ( Figure 1e ) [4] . Since the upper unglycosylated band migrated faster compared with type 1 PrP Sc from MM1, these heterogeneous bands were different from the cooccurrence of types 1 (21 kDa) and 2 (19 kDa) PrP Sc . In contrast, MV2C and MM2C had only type 2 PrP Sc located at 19 kDa. In the western blot analysis using the PrP Sc type-specific antibodies, MV2K and MV2K + C had large amounts of T1-reactive PrP Sc in addition to T2-reactive PrP Sc ( Figure 1f ). The amounts of T1-reactive PrP Sc in the MV2K cerebrum were relatively low compared with the cerebellum, suggesting regional variability in the ratio of the amounts of T1-reactive PrP Sc to the amounts of T2-reactive PrP Sc . The low amounts of T1-reactive PrP Sc in the MV2K cerebrum accounted for the absence of the 20 kDa (upper) unglycosylated band in the western blot using the 3F4 antibody, since conventional western blot analysis using antibodies that react with all PrP Sc types cannot detect a coexisting minority component [26] . In addition, the T2-reactive PrP Sc in the cerebellum of MV2K or MV2K + C consisted of ladder-like multiple fragments, which were quite different from the T2-reactive PrP Sc in the cerebrum. Thus, MV2K and MV2K + C showed similar molecular properties in the western blot analysis using the PrP Sc type-specific antibodies. By contrast, MV2C and MM2C had predominant T2-reactive PrP Sc with only trace amounts of T1-reactive PrP Sc as reported [26, 27] . MM1 had predominant T1-reactive PrP Sc with trace amounts of T2-reactive PrP Sc as reported [28] . Taken together, MV2C was clearly different from the other MV2 subgroups in the molecular typing as well, whereas MV2K and MV2K + C could not be distinguished by molecular typing even with the PrP Sc type-specific antibodies.
Transmission typing of MV2
To characterize further the MV2 subgroups, we then performed transmission experiments using PrP-humanized mice. These knock-in mice (Ki-Hu129M/M, Ki-Hu129M/ V, or Ki-Hu129V/V) express human PrP with either the 129M/M, M/V, or V/V genotype at the same level. Since the expression level of PrP affects the susceptibility to PrP Sc infection regardless of the PrP genotype, these knock-in mice have an advantage over transgenic mice for evaluating the susceptibility among the genotypes [18] . After intracerebral challenge with the MV2K brain material, Ki-Hu129M/M and Ki-Hu129M/V showed much longer incubation times compared with those of Ki-Hu129V/V (Figure 2) . Inoculation of the MV2K + C brain material resulted in the same transmission patterns as those of MV2K. Furthermore, the histopathological phenotypes of MV2K and those of MV2K + C in the inoculated mice were also indistinguishable (Figure 3a, b) . Ki-Hu129M/M showed variously sized, round, plaquetype PrP deposits throughout the cerebral grey matter, white matter, striatum, and thalamus. Ki-Hu129M/V had fewer PrP plaques compared with the Ki-Hu129M/M. In Ki-Hu129V/V, PrP plaques were restricted to within the white matter. Large confluent vacuoles or perivacuolar PrP deposition, which are characteristics of MV2C/ MM2C, were absent in the MV2K + C-inoculated mice. The conventional western blot analysis of PrP Sc in the brains from MV2K-or MV2K + C-inoculated mice using the 3F4 antibody revealed that Ki-Hu129M/M produced (Figure 3c ). Western blot analysis using the PrP Sc typespecific antibodies revealed that the amounts of T1-reactive PrP Sc gradually decreased from Ki-Hu129M/M to Ki-Hu129M/V to Ki-Hu129V/V, while the amounts of T2-reactive PrP Sc gradually increased from Ki-Hu129M/ M to Ki-Hu129M/V to Ki-Hu129V/V (Figure 3d ). Thus, MV2K and MV2K + C could also not be distinguished by transmission typing. , and 329 ± 3 days (4/4), respectively. The mean incubation times of MV2K + C-inoculated Ki-Hu129M/M, Ki-Hu129M/V, and Ki-Hu129V/V were 600 ± 22 days (6/6), 638 ± 11 days (7/7), and 332 ± 15 days (4/4), respectively. The mean incubation times of VV2-inoculated Ki-Hu129M/M, Ki-Hu129M/V, and Ki-Hu129V/V were 633 ± 49 days (6/6), 788 ± 30 days (4/4), and 302 ± 9 days (7/7), respectively. The mean incubation times of MM1-inoculated Ki-Hu129M/M, Ki-Hu129M/V, and Ki-Hu129V/V were 467 ± 24 days (8/8), 490 ± 26 days (5/5), and 774 ± 32 days (6/6), respectively. The details of the transmission experiments of VV2 or MM1 using Ki-Hu129M/M and Ki-Hu129V/V have been reported previously [25, 29] . . The mean signal intensities of MM1 were assigned as 100 /mm 2 in each experiment using 3F4 or T1 antibody, and those of MM2C were assigned as 100 /mm 2 in each experiment using T2 antibody. All experiments were repeated independently at least three times.
Modelling of MV2
disease after a long incubation period (Figure 2 ). These mice showed PrP plaques in the cerebral grey matter, white matter, striatum, and thalamus (Figure 4a, b) . As reported previously [29] , VV2-inoculated Ki-Hu129M/M had more PrP plaques throughout the brain, whereas VV2-inoculated Ki-Hu129V/V showed restricted plaque distribution within the white matter. Figure S2 ). Thus, M2C PrP Sc lacked infectivity to the PrPhumanized mice.
Discussion
We performed a comprehensive analysis of the MV2 subgroups, i.e., MV2C, MV2K, and MV2K + C, and resolved their complicated pathogenesis. MV2C showed close similarity to MM2C in the histopathological and molecular analyses and could be easily discriminated from the other MV2 subgroups. By contrast, MV2K and MV2K + C showed the same molecular type and the same transmission type. Sc into the PrPhumanized mice to gain insight into the reason why MV2K and MV2K + C could not be distinguished by transmission typing. These transmission experiments revealed that M2C PrP Sc lacked infectivity to the PrP-humanized mice. Therefore, the present data lead us to surmise that MV2K + C may also contain M2C PrP Sc lacking infectivity to the PrP-humanized mice in addition to Mi and V2 PrP Sc . Further study will be needed to verify that MV2C and MM2C are identical in transmission typing as well as histotyping and molecular typing. To grasp the whole picture of the phenotypic variability and PrP Sc strain diversity in the MV2 subgroups, a transmission study of MV2C is in progress using the PrP-humanized mice.
The Sc is difficult with conventional western blot analysis and requires strict conditions for PK-digestion and high resolution gel electrophoresis systems, e.g., 10-20% gradient Tris-glycine long gels or Bis-tris long gels (Figure 4e ) [11] . However, they could be easily distinguished by the PrP Sc type-specific antibodies in the present study. Moreover, the cooccurrence of the intermediate type PrP
Sc and type 2 PrP Sc was recapitulated in the animal model for the first time. Parchi and colleagues once proposed to designate the atypical type 2 as type 2 +20kDa [12] , but they have never used this nomenclature thereafter. To characterize MV2 cases more adequately, we propose refined nomenclature as follows: MV2C, MVi + 2, or MVi + 2C ( Table 1 ). The present study suggests that pure type 2 PrP Sc in MV2C and the mixture of the intermediate type PrP . The mean signal intensities of MM1-inoculated Ki-Hu129M/M were assigned as 100 /mm 2 in each experiment using 3F4 or T1 antibody, and those of MV2K + C-inoculated Ki-Hu129V/V were assigned as 100 /mm 2 in each experiment using T2 antibody. All experiments were repeated independently at least three times.
component of kuru plaques and is directly associated with the neuropathological phenotype. The amounts of Mi PrP Sc might vary among brain regions, as shown in the western blot analysis of the MVi + 2 brain in the present study. Unfortunately, we could not test this possibility in detail because additional brain materials were not available. However, in the histopathological analysis, the abundance of kuru plaques varied among brain regions in the MVi + 2 or MVi + 2C patient (Additional file 1: Figure S1 ). The prominent kuru plaque formation in the cerebellum of MVi + 2 or MVi + 2C may indicate that histopathological and molecular analyses of the cerebellum would be useful to detect Mi PrP Sc and kuru plaques, which are two phenotypic hallmarks of MVi + 2 or MVi + 2C. Meanwhile, even in our comprehensive analysis, the sole difference between MVi + 2 and MVi + 2C was the presence of MV2C/MM2C pathology. Since MVi + 2C cases with the very focal MV2C/MM2C pathology can be misdiagnosed as MVi + 2 [10] , further study will be needed to assess whether MVi + 2 and MVi + 2C are distinguishable in their clinical features. Although we believe that the refined nomenclature proposed here would contribute to clarifying the complicated issues around the MV2 subgroups, the number of MV2 cases included in the present study was very limited because MV2C, MVi + 2, and MVi + 2C are rare in Japan compared with Western countries, reflecting the very low prevalence of the 129M/V genotype in the healthy population [33] . We analyzed a total of 232 cases with sCJD and found only 5 cases with MVi + 2, 2 cases with MV2C (one of the patients carried the M232R mutation on the 129M allele), and 1 case with MVi + 2C. Although typical cases of each subgroup were . The mean signal intensities of MM1-inoculated Ki-Hu129M/M were assigned as 100 /mm 2 in each experiment using the 3F4 or T1 antibody, and those of VV2-inoculated Ki-Hu129V/V were assigned as 100 /mm 2 in each experiment using the T2 antibody. All experiments were repeated independently at least three times. selected for the present study, we cannot exclude the possibility of phenotypic variation within each subgroup. It remains unclear why M2C PrP Sc lacked infectivity to the PrP-humanized mice despite the fact that they could propagate in the MM2C/MV2C patient brain. Although there was no evidence of successful transmission in the present study, very low infectivity of M2C PrP Sc was reported in a transmission study using other PrP-humanized knock-in mouse lines [13] . The disease duration of MM2C/ MV2C patients is the longest among sCJD subgroups [5] , suggesting slow propagation of M2C PrP Sc . Therefore, M2C PrP Sc may replicate less efficiently and take a longer time to propagate compared with the other PrP Sc strains. Dura mater graft-associated CJD with kuru plaques (p-dCJD) might be caused by infection of V2 PrP Sc and/or Mi PrP Sc to individuals with the 129M/M genotype. We reported previously that transmission of VV2 to animals with the 129M/M genotype caused p-dCJD like phenotype, i.e., widespread PrP plaques and an accumulation of Mi PrP Sc , and that the transmission properties of p-dCJD were identical to those of VV2 [29] . It has been reported that the transmission properties of MVi + 2 were the same as those of VV2 [13, 36] . In the present study, the transmission properties of MVi + 2C were also identical to those of VV2, and the transmission of MVi + 2 or MVi + 2C to animals with the 129M/M genotype caused p-dCJD like phenotype. These results suggest that p-dCJD is caused by infection of V2 PrP Sc and/or Mi PrP Sc from sCJD patients with VV2, MVi + 2, or MVi + 2C. Indeed, the incidence rate of p-dCJD among total dura mater graft-associated CJD is 32% [37] , which is close to the sum total of the incidence of VV2 (15%), MVi + 2 (8%), and MVi + 2C (3%) in sCJD [5] . Since Mi PrP Sc in individuals with the 129M/M 
